{"entity":{"id":"ingo-mellinghoff","kind":"person","name":"Ingo K. Mellinghoff","aka":[],"tldr":"Led INDIGO, the trial that made vorasidenib the first targeted therapy for low-grade IDH-mutant glioma.","summary":"Ingo Mellinghoff was principal investigator of INDIGO, which showed the dual IDH1/2 inhibitor vorasidenib more than doubles progression-free survival and delays the need for chemoradiotherapy in grade 2 IDH-mutant glioma, the first targeted drug approved for glioma and a shift away from early radiation for young patients. His laboratory studies signalling and metabolism in glioma and he leads neuro-oncology drug development at MSKCC.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mellinghoff%20IK%5BAuthor%5D%20glioma%20vorasidenib"}],"tags":["glioma","idh","targeted-therapy"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":["idh"],"drugs":["vorasidenib"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["indigo"],"people":[],"bottlenecks":[],"keyPapers":["paper-indigo-nejm-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Department of Neurology, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Glioma","IDH-mutant tumours","Targeted therapy","Neuro-oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mellinghoff%20IK%5BAuthor%5D%20glioma%20vorasidenib"}],"papers":[{"title":"Vorasidenib in IDH1- or IDH2-mutant low-grade glioma (INDIGO)","journal":"NEJM","year":2023,"doi":"10.1056/NEJMoa2304194"},{"title":"Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; results of a first-in-human phase I trial","journal":"Clinical Cancer Research","year":2021,"doi":"10.1158/1078-0432.CCR-20-4164"}],"orcid":"0000-0002-4347-8149"},"route":"/people/ingo-mellinghoff/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"target":[{"id":"idh","kind":"target","name":"IDH1 / IDH2","route":"/targets/idh/"}],"drug":[{"id":"vorasidenib","kind":"drug","name":"Vorasidenib","route":"/drugs/vorasidenib/"}],"institution":[{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"}],"trial":[{"id":"indigo","kind":"trial","name":"INDIGO","route":"/trials/indigo/"}],"paper":[{"id":"paper-indigo-nejm-2023","kind":"paper","name":"INDIGO: vorasidenib, the first targeted drug for IDH-mutant low-grade glioma","route":"/key-papers/paper-indigo-nejm-2023/"}],"roadmap":[{"id":"epigenetics-roadmap","kind":"roadmap","name":"Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome","route":"/roadmaps/epigenetics-roadmap/"}]}}